Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Mar 1;11(3):293-299.
doi: 10.1001/jamaoncol.2024.6160.

Urinary DNA Methylation Test for Bladder Cancer Diagnosis

In Gab Jeong  1 , Sung-Cheol Yun  2 , Hong Koo Ha  3 , Sung Gu Kang  4 , Sangchul Lee  5 , Sungchan Park  6 , Hyun Hwan Sung  7 , Sun Il Kim  8 , Eu Chang Hwang  9 , Kyung Cheol Moon  10 , Cheol Kwak  11
Affiliations
Comparative Study

Urinary DNA Methylation Test for Bladder Cancer Diagnosis

In Gab Jeong et al. JAMA Oncol. .

Abstract

Importance: An accurate noninvasive biomarker test is needed for the early diagnosis of bladder cancer.

Objective: To evaluate the performance of a urinary DNA methylation test (PENK methylation) and compare its diagnostic accuracy with that of the nuclear matrix protein 22 (NMP22) test or urine cytology test.

Design, setting, and participants: In this prospective multicenter study at 10 sites in the Republic of Korea, individuals 40 years and older with hematuria undergoing cystoscopy within 3 months between March 11, 2022, and May 30, 2024, participated. The study participants were evaluated for bladder cancer using a urinary DNA methylation test.

Exposure: Urinary DNA methylation test, NMP22 test, and urine cytology test.

Main outcomes and measures: The primary outcomes were the sensitivity and specificity of the urinary DNA methylation test for high-grade or invasive bladder cancer. Secondary objectives included the accuracy of the test for overall bladder cancer (all stages and grades) and the comparison of sensitivities and specificities for bladder cancer between the urinary DNA methylation test and the NMP22 test or urine cytology test.

Results: Among the 1099 participants, 614 (55.9%) were male; participants had a mean (SD) age of 65 (10) years. Of the 1099 participants, 219 and 176 participants had bladder cancer and high-grade or invasive bladder cancer, respectively. The urinary DNA methylation test had sensitivity and specificity for high-grade or invasive bladder cancer of 89.2% (95% CI, 84.6%-93.8%) and 87.8% (95% CI, 85.6%-89.9%), respectively. Sensitivity and specificity for overall bladder cancer were 78.1% (95% CI, 72.6%-83.6%) and 88.8% (95% CI, 86.7%-90.8%), respectively. The positive predictive value for high-grade or invasive bladder cancer was 61.3% (95% CI, 55.4%-67.3%), and the negative predictive value was 97.6% (95% CI, 96.6%-98.7%). In comparison with the NMP22 test or urine cytology test, the urinary DNA methylation test showed significantly superior sensitivity for high-grade or invasive bladder cancer and overall bladder cancer.

Conclusions and relevance: In this prospective multicenter study of individuals with hematuria, the urinary DNA methylation test showed 89% sensitivity for detecting high-grade or invasive bladder cancer, outperforming the NMP22 test or urine cytology test with high specificity. While this test had an excellent negative predictive value, its positive predictive value was suboptimal.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

References

    1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi:10.3322/caac.21763 - DOI - PubMed
    1. Lobo N, Afferi L, Moschini M, et al. . Epidemiology, screening, and prevention of bladder cancer. Eur Urol Oncol. 2022;5(6):628-639. doi:10.1016/j.euo.2022.10.003 - DOI - PubMed
    1. Babjuk M, Burger M, Capoun O, et al. . European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75-94. doi:10.1016/j.eururo.2021.08.010 - DOI - PubMed
    1. Maas M, Todenhöfer T, Black PC. Urine biomarkers in bladder cancer—current status and future perspectives. Nat Rev Urol. 2023;20(10):597-614. doi:10.1038/s41585-023-00773-8 - DOI - PubMed
    1. Tomiyama E, Fujita K, Hashimoto M, Uemura H, Nonomura N. Urinary markers for bladder cancer diagnosis: a review of current status and future challenges. Int J Urol. 2024;31(3):208-219. doi:10.1111/iju.15338 - DOI - PubMed